Liposomal muramyl tripeptide phosphatidyl ethanolamine: Ifosfamide-containing chemotherapy in osteosarcoma

Future Oncology

Volumn 2, Issue 3, 2006, Pages 333-343

  Anderson, Peter ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biological cancer theraphy; Cancer biotherapy; Cancer chemotherapy; Ifosfamide; Liposomes; Lung metastases; Mesna; Muramyl tripeptide phosphatidyl ethanolamine; Osteosarcoma

Indexed keywords

APREPITANT; CARBOPLATIN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DICLOFENAC; DIOLEOYLPHOSPHATIDYLSERINE; DOXORUBICIN; DRUG CARRIER; ETOPOSIDE; GEMCITABINE; IBUPROFEN; IFOSFAMIDE; INTERLEUKIN 2; LIPOSOME; MESNA; METHOTREXATE; METHYLENE BLUE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OLEOYLPALMITOYLLECITHIN; PALONOSETRON; PARACETAMOL; PETHIDINE; PHOSPHATE; PHOSPHATIDYLCHOLINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RUBITECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BIOLOGICAL THERAPY; BLEEDING; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILL; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE CONTROL; DIZZINESS; DOG; DRUG ACCUMULATION; DRUG CHOICE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; GLOMERULOPATHY; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOTHERMIA; INFECTION; KIDNEY PROXIMAL TUBULE; LIMB PAIN; LUNG METASTASIS; MALAISE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; OUTPATIENT CARE; PAIN; PERICARDITIS; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOMATOLOGY; TACHYCARDIA; TACHYPNEA; THROMBOSIS; TREATMENT FAILURE; VOMITING; WASTING SYNDROME;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; HUMANS; IFOSFAMIDE; LIPOSOMES; OSTEOSARCOMA; PHOSPHATIDYLETHANOLAMINES;

EID: 33745492007     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.3.333     Document Type: Article

References (83)

1. Herzog CE: Overview of sarcomas in the adolescent and young adult population: J. Pediatr. Hematol. Oncol. 27(4), 215-218 (2005).
2. Ferguson WS, Goorin AM: Current treatment of osteosarcoma. Cancer Invest. 19(3), 292-315 (2001).
3. Meyers PA, Schwartz CL, Krailo M et al.: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 23(9), 2004-2011 (2005).
4. Nardin A, Lefebvre ML, Labroquere K, Favaro D, Abastado J-P: Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Current Cancer Drug Targets 6(1), 561-571 (2006).
5. Kerbusch T, Mathot RA, Keizer HJ et al.: Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab. Dispos. 29(7), 967-975 (2001).
6. Bielack SS, Kempf-Bielack B, Delling G et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 20(3), 776-790 (2002).
7. Goorin AM, Harris MB, Bernstein M et al.: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J. Clin. Oncol. 20(2), 426-433 (2002).
8. Hawkins DS, Arndt CA: Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98(11), 2447-2456 (2003).
9. Anderson P: Osteosarcoma relapse: expect the worst, but hope for the best. Pediatr. Blood Cancer (2005) (Epub ahead of print).
10. Crompton BD, Goldsby RE, Weinberg VK, Feren R, O'Donnell RJ, Ablin AR: Survival after recurrence of osteosarcoma: a 20-year experience at a single institution. Pediatr. Blood Cancer (2005) (Epub ahead of print).
11. Machak GN, Tkachev SI, Solovyev YN et al.: Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin. Proc. 78(2), 147-155 (2003).
12. DeLaney TF, Park L, Goldberg SI et al.: Radiation therapy for local control of osteosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 57(Suppl. 2), S449 (2003).
13. Mori K, Redini F, Gouin F, Cherrier B, Heymann D: Osteosarcoma: current status of immunotherapy and future trends (Review). Oncol. Rep. 15(3), 693-700 (2006).
14. Klenner T, Wingen F, Keppler BK, Krempien B, Schmahl D: Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J. Cancer Res. Clin. Oncol. 116(4), 341-350 (1990).
15. Hoskin PJ: Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat. Rev. 29(4), 321-327 (2003).
16. Heymann D, Ory B, Gouin F, Green JR, Redini F: Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends. Mol. Med. 10(7), 337-343 (2004).
17. Hosain F, Spencer RP, Couthon HM, Sturtz GL: Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. J. Nucl. Med. 37(1), 105-107 (1996).
18. Heymann D, Ory B, Blanchard F et al.: Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37(1), 74-86 (2005).
19. Anderson PM, Wiseman GA, Erlandson L et al.: Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin. Cancer Res. 11(19 Pt 1), 6895-6900 (2005).
20. Chedid L, Audibert F, Johnson AG: Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog. Allergy 25, 63-105 (1978).
21. Cryan SA: Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7(1), E20-41 (2005).
22. Zamboni WC: Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin. Cancer Res. 11(23), 8230-8234 (2005).
23. O'Brien ME, Wigler N, Inbar M et al.: Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15(3), 440-449 (2004).
24. Gabizon AA, Lyass O, Berry GJ, Wildgust M: Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest. 22(5), 663-669 (2004).
25. Laginha KM, Verwoert S, Charrois GJ, Allen TM: Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin. Cancer Res. 11(19 Pt 1), 6944-6949 (2005).
26. Khanna C, Hasz DE, Klausner JS, Anderson PM: Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin. Cancer Res. 2(4), 721-734 (1996).
27. Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS: Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 79(7), 1409-1421 (1997).
28. Khanna C, Waldrep JC, Anderson PM et al.: Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J. Pharm. Pharmacol. 49(10), 960-971 (1997).
29. Skubitz KM, Anderson PM: Inhalational interleukin-2 liposomes for pulmonary metastases: a Phase I clinical trial. Anticancer Drugs 11(7), 555-563 (2000).
30. Gorlick R, Anderson P, Andrulis I et al.: Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin. Cancer Res. 9(15), 5442-5453 (2003).
31. Glaberman U, Rabinowitz I, Verschraegen CF: Alternative administration of camptothecin analogues. Expert Opin. Drug Deliv. 2(2), 323-333 (2005).
32. Key ME, Talmadge JE, Fogler WE, Bucana C, Fidler IJ: Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J. Natl Cancer Inst. 69 (5), 1198-1198 (1982).
33. Koff WC, Fidler IJ, Showalter SD et al.: Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Science 224(4652), 1007-1009 (1984).
34. Talmadge JE, Schneider M, Collins M, Phillips H, Herberman RB, Wiltrout RH: Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE: J. Immunol. 135(2), 1477-1483 (1985).
35. Fogler WE, Fidler IJ: Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages. Cancer Res. 45(1), 14-18 (1985).
36. Whitworth PW, Pak CC, Esgro J, Kleinerman ES, Fidler IJ: Macrophages and cancer. Cancer Metastasis Rev. 8(4), 319-351 (1990).
37. Fidler IJ, Kleinerman ES: Therapy of cancer metastasis by systemic activation of macrophages: from the bench to the clinic. Res. Immunol. 144(4), 284-287; discussion 294-298 (1993).
38. Galligioni E, Favaro D, Santarosa M et al.: Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response. Clin. Cancer Res. 1(5), 493-499 (1995).
39. Frost H, Murray JL, Chaudri HA, Van Damme J: Interleukin-6 induction by a muramyltripeptide derivative in cancer patients. J. Biol. Response Mod. 9(2), 160-166 (1990).
40. Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N: Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J. Clin. Oncol. 10(8), 1310-1316 (1992).
41. Liebes L, Walsh CM, Chachoua A et al.: Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a Phase II study in patients with metastatic melanoma. J. Natl Cancer Inst. 84(9), 694-699 (1992).
42. Maeda M, Asano T, Kleinerman ES: Anti- (tumor necrosis factor) alters the response of human monocytes to tiposomal muramyl tripeptide. Cancer Immunol. Immunother. 37(3), 203-208 (1993).
43. Goldbach P, Dumont S, Kessler R, Poindron P, Stamm A: In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-γ and muramyl tripeptide. Am. J. Physiol. 270 (3 Pt 1), L429-434 (1996).
44. Asano T, McWatters A, An T, Matsushima K, Kleinerman ES: Liposomal muramyl tripeptide up-regulates interleukin-1 α, interleukin-1 β, tumor necrosis factor-α, interleukin-6 and interleukin-8 gene expression in human monocytes. J. Pharmacol. Exp. Ther. 268(2), 1032-1039 (1994).
45. Murray JL, Kleinerman ES, Cunningham JE et al.: Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J. Clin. Oncol. 7(12), 1915-1925 (1989).
46. Asano T, McIntyre BW, Bednarczyk JL, Wygant JN, Kleinerman ES: Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Oncol. Res. 7(5), 253-257 (1995).
47. Kleinerman ES, Raymond AK, Bucana CD et al.: Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol. Immunother. 34(4), 211-220 (1992).
48. Kleinerman ES, Maeda M, Jaffe N: Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat. Res. 62, 101-107 (1993).
49. Killion JJ, Kleinerman ES, Wilson MR, Tanaka M, Fidler IJ: Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents. Oncol. Res. 4(10), 413-418 (1992).
50. Asano T, Fujimaki W, McWatters A, An T, Matsushima K, Kleinerman ES: Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression. Cancer Immunol. Immunother. 37(6), 408-411 (1993).
51. Lafleur EA, Koshkina NV, Stewart J et al.: Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin. Cancer Res. 10(23), 8114-8119 (2004).
52. Duan X, Zhou Z, Jia SF, Colvin M, Lafleur EA, Kleinerman ES: Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/ Fas-ligand pathway. Clin. Cancer Res. 10(2), 777-783 (2004).
53. Duan X, Jia SF, Koshkina N, Kleinerman: Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 106(6), 1382-1388 (2006).
54. Koshkina NV, Kleinerman ES: Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int. J. Cancer 116(3), 458-463 (2005).
55. Worth LL, Lafleur EA, Jia SF, Kleinerman ES: Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol. Rep. 9(4), 823-827 (2002).
56. Zhou Z, Lafleur EA, Koshkina NV, Worth LL, Lester MS, Kleinerman ES: Interleukin- 12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol. Cancer Res. 3(12), 685-691 (2005).
57. 3H] muramyl tripeptide phosphatidylethanolamine in mice. J. Immunol. 135(2), 1372-1377 (1985).
58. Gay B, Cardot JM, Schnell C, van Hoogevest P, Gygax D: Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE: J. Pharm. Sci. 82(10), 997-1001 (1993).
59. MacEwen EG, Kurzman ID, Rosenthal RC et al.: Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl Cancer Inst. 81(12), 935-938 (1989).
60. MacEwen EG, Kurzman ID, Helfand S et al.: Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J. Drug Target 2(5), 391-396 (1994).
61. MacEwen EG, Kurzman ID: Canine osteosarcoma: amputation and chemoimmunotherapy. Vet Clin. North Am. Small Anim. Pract. 26(1), 123-133 (1996).
62. Kurzman ID, MacEwen EG, Rosenthal RC et al.: Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin. Cancer Res. 1(12), 1595-1601 (1995).
63. Vail DM, MacEwen EG, Kurzman ID et al.: Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin. Cancer Res. 1(10), 1165-1170 (1995).
64. Kurzman ID, Shi F, Vail DM, MacEwen EG: In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother. Radiopharm. 14(2), 121-128 (1999).
65. Creaven PJ, Cowens JW, Brenner DE et al.: Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J. Biol. Response Mod. 9(5), 492-498 (1990).
66. Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ: Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res. 49(16), 4665-4670 (1989).
67. Fujimaki W, Griffin JR, Kleinerman ES: Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation? Cancer Immunol. Immunother. 36(1), 45-51 (1993).
68. Fedorocko P, Hoferova Z, Hofer M, Brezani P: Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities. Neoplasma 50(3), 176-184 (2003).
69. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N: Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am. J. Clin. Oncol. 18(2), 93-99 (1995).
70. Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N: Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J. Immunother. Emphasis Tumor Immunol. 17(3), 181-193 (1995).
71. Chou AJ, Merola PR, Wexler LH et al.: Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104(10), 2214-2221 (2005).
72. Romet-Lemonne JL, Mills B, Fridman WH, Munsell M: Prospectively planned analysis of data from a phase III study of liposomal muramyltripeptide phosphatidylethanolamine in the treatment of osteosarcoma. J. Clin. Oncol. 23(26), 6437-6438 (2005).
73. Gano JB, Kleinerman ES: Liposomal MTP-PE: J. Pediatr. Oncol. Nurs. 11(4), 161-163 (1994).
74. Gano JB, Kleinerman ES: Liposomal MTP-PE: a promising new biologic response modifier. Oncol. Nurs. Forum 22(5), 809-816 (1995).
75. Gano JB, Kleinerman ES: Administration of liposomal MTP-PE by the local physician: the role of the research nurse. Cancer Pract. 3(1), 42-46 (1995).
76. Skinner R, Cotterill SJ, Stevens MC: Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom, Children's Cancer Study Group. Br. J. Cancer 82(10), 1636-1645 (2000).
77. Skinner R: Chronic ifosfamide nephrotoxicity in children. Med. Pediatr. Oncol. 41(3), 190-197 (2003).
78. Kerbusch T, de Kraker J, Keizer HJ et al.: Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin. Pharmacokinet. 40(1), 41-62 (2001).
79. Skubitz KM, Hamdan H, Thompson RC Jr: Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 72(10), 2963-2969 (1993).
80. Van Winkle P, Angiolillo A, Krailo M et al.: Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr. Blood Cancer 44(4), 338-347 (2005).
81. David KA, Picus J: Evaluating risk factors for the development of ifosfamide encephalopathy. Am. J. Clin. Oncol. 28(3), 277-80 (2005).
82. Raj AB, Bertolone SJ, Jaffe N: Methylene blue reversal of ifosfamide-related encephalopathy. J. Pediatr. Hematol. Oncol. 26(2), 116 (2004).
83. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br. J. Cancer 82(2), 291-294 (2000).